Novartis Ag (NVS) Cash & Equivalents (2009 - 2025)

Novartis Ag (NVS) has 12 years of Cash & Equivalents data on file, last reported at $2.6 billion in Q4 2025.

• Quarterly Cash & Equivalents rose 965.7% year-over-year to $2.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 billion (up 965.7% YoY) and the FY2025 annual result came in at $2.6 billion, up 965.7% from the prior year.
• Cash & Equivalents eased to $2.6 billion in Q4 2025 per NVS's latest filing, from $6.7 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $13.4 billion in Q4 2023, with the low at -$70.0 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $3.7 billion, with a median of $242.0 million recorded in 2024.
• Year-over-year, Cash & Equivalents tumbled 1066.67% in 2022 and surged 12130.34% in 2023.
• Novartis Ag's Cash & Equivalents stood at $12.4 billion in 2021, then plunged by 39.41% to $7.5 billion in 2022, then surged by 78.17% to $13.4 billion in 2023, then tumbled by 98.19% to $242.0 million in 2024, then soared by 965.7% to $2.6 billion in 2025.
• Business Quant data shows NVS's Cash & Equivalents at $2.6 billion in Q4 2025, $6.7 billion in Q2 2025, and $242.0 million in Q4 2024.